Trial Profile
A First-in-Human, Multi-centre, Open-label, Phase 1a/b Clinical Study With RNA Oligonucleotide Drug MTL-CEBPA to Investigate Its Safety, Tolerability, and Antitumour Activity in Patients With Advanced Liver Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 29 Nov 2023
Price :
$35
*
At a glance
- Drugs MTL CEBPA (Primary) ; Sorafenib
- Indications Colorectal cancer; Liver cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms OUTREACH
- Sponsors MiNA Therapeutics
- 24 Nov 2023 Planned End Date changed from 1 Jan 2023 to 31 Dec 2024.
- 24 Nov 2023 Planned primary completion date changed from 1 Nov 2022 to 1 Jan 2024.
- 04 Apr 2022 Planned End Date changed from 1 Jan 2022 to 1 Jan 2023.